# Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation

> **NCT05910970** · PHASE3 · UNKNOWN · sponsor: **Guangxi Medical University** · enrollment: 200 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Recurrence
- Immune Checkpoint Inhibitor

## Interventions

- **DRUG:** Adjuvant tislelizumab plus lenvatinib
- **DRUG:** Adjuvant tislelizumab

## Key facts

- **NCT ID:** NCT05910970
- **Lead sponsor:** Guangxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-02-15
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05910970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05910970, "Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05910970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*